Endothelin-1 and Endothelin-3 Promote Invasive Behavior via Hypoxia-Inducible Factor-1α in Human Melanoma Cells

Endothelin (ET) B receptor (ETBR), which is overexpressed in human cutaneous melanomas, promotes tumorigenesis upon activation by ET-1 or ET-3, thus representing a potential novel therapeutic target. Hypoxia-inducible factor-1α (HIF-1α) is the transcriptional factor that conveys signaling elicited by hypoxia and growth factor receptors. Here, we investigated the interplay between ET axis and hypoxia in primary and metastatic melanoma cell lines. We report that under normoxic conditions, ETBR activation by ET-1/ET-3 enhances vascular endothelial growth factor (VEGF) up-regulation, cyclooxygenase (COX)-1/COX-2 protein expression and COX-2 promoter activity, prostaglandin E2 (PGE2) production, and do so to a greater extent under hypoxia. Moreover, COX-1/COX-2 inhibitors block ET-induced PGE2 and VEGF secretion, matrix metalloproteinase (MMP) activation, and cell invasion, indicating that both enzymes function as downstream mediators of ET-induced invasive properties. The ETBR selective antagonist BQ788 or transfection with ETBR small interfering RNA (siRNA) block the ET-mediated effects. ETs also increase HIF-1α expression under both normoxic and hypoxic conditions and its silencing by siRNA desensitizes COX-2 transcriptional activity, PGE2 and VEGF production, and MMP activation in response to ET-3, implicating, for the first time, HIF-1α/COX as downstream targets of ETBR signaling leading to invasiveness. In melanoma xenografts, specific ETBR antagonist suppresses tumor growth, neovascularization, and invasiveness-related factors. Collectively, these results identify a new mechanism whereby ET-1/ET-3/ETBR axis can promote and interact with the HIF-1α–dependent machinery to amplify the COX-mediated invasive behavior of melanoma. New therapeutic strategies using specific ETBR antagonist could provide an improved approach to the treatment of melanoma by inhibiting tumor growth and progression. [Cancer Res 2007;67(4):1725–34]

[1]  M. Hendrix,et al.  Influence of the microenvironment on melanoma cell fate determination and phenotype. , 2006, Cancer research.

[2]  D. Qualtrough,et al.  Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. , 2006, Cancer research.

[3]  J. Pouysségur,et al.  Hypoxia signalling in cancer and approaches to enforce tumour regression , 2006, Nature.

[4]  B. Chwirot,et al.  Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression , 2006, Melanoma research.

[5]  M. Herlyn.  Molecular targets in melanoma: Strategies and challenges for diagnosis and therapy , 2006, International journal of cancer.

[6]  K. Lundholm,et al.  Cyclooxygenase inhibition in early onset of tumor growth and related angiogenesis evaluated in EP1 and EP3 knockout tumor-bearing mice , 2006, Angiogenesis.

[7]  Amato J Giaccia,et al.  The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. , 2005, Cancer cell.

[8]  D. Federman,et al.  Use of Cyclooxygenase Inhibitors and Risk of Melanoma in High‐Risk Patients , 2005, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[9]  G. Babcock,et al.  alpha-Melanocortin and endothelin-1 activate antiapoptotic pathways and reduce DNA damage in human melanocytes. , 2005, Cancer research.

[10]  P. Khavari,et al.  Melanoma genetics and the development of rational therapeutics. , 2005, The Journal of clinical investigation.

[11]  I. Stamenkovic,et al.  Endothelin Receptor B Inhibition Triggers Apoptosis and Enhances Angiogenesis in Melanomas , 2004, Cancer Research.

[12]  A. Hachiya,et al.  Biphasic expression of two paracrine melanogenic cytokines, stem cell factor and endothelin-1, in ultraviolet B-induced human melanogenesis. , 2004, The American journal of pathology.

[13]  F. Spinella,et al.  Endothelin-1-induced Prostaglandin E2-EP2, EP4 Signaling Regulates Vascular Endothelial Growth Factor Production and Ovarian Carcinoma Cell Invasion* , 2004, Journal of Biological Chemistry.

[14]  M. Pierotti,et al.  BRAF alterations are associated with complex mutational profiles in malignant melanoma , 2004, Oncogene.

[15]  G. Saed,et al.  Hypoxia up-regulates the effects of prostaglandin E2 on tumor angiogenesis in ovarian cancer cells. , 2004, Gynecologic oncology.

[16]  F. Spinella,et al.  Inhibition of Cyclooxygenase-1 and -2 Expression by Targeting the Endothelin A Receptor in Human Ovarian Carcinoma Cells , 2004, Clinical Cancer Research.

[17]  G. T. Bowden,et al.  UVA-mediated activation of signaling pathways involved in skin tumor promotion and progression. , 2004, Seminars in cancer biology.

[18]  F. Spinella,et al.  Endothelin B Receptor Blockade Inhibits Dynamics of Cell Interactions and Communications in Melanoma Cell Progression , 2004, Cancer Research.

[19]  C. Berking,et al.  Induction of Melanoma Phenotypes in Human Skin by Growth Factors and Ultraviolet B , 2004, Cancer Research.

[20]  A. Giaccia,et al.  HIF-1 as a target for drug development , 2003, Nature Reviews Drug Discovery.

[21]  A. Harris,et al.  Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. , 2003, Melanoma research.

[22]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[23]  D. Nettelbeck,et al.  Cyclooxygenase-2 promoter for tumour-specific targeting of adenoviral vectors to melanoma , 2003, Melanoma research.

[24]  G. Semenza,et al.  Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. , 2003, Cancer research.

[25]  G. Semenza,et al.  Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. , 2003, Cancer research.

[26]  F. Spinella,et al.  Emerging role of endothelin-1 in tumor angiogenesis , 2003, Trends in Endocrinology & Metabolism.

[27]  A. Levine,et al.  Prostaglandin E2 Induces Hypoxia-inducible Factor-1α Stabilization and Nuclear Localization in a Human Prostate Cancer Cell Line* , 2002, The Journal of Biological Chemistry.

[28]  R. Schneider,et al.  UV-induction of keratinocyte endothelin-1 downregulates E-cadherin in melanocytes and melanoma cells. , 2002, The Journal of clinical investigation.

[29]  F. Spinella,et al.  Endothelin-1 Induces Vascular Endothelial Growth Factor by Increasing Hypoxia-inducible Factor-1α in Ovarian Carcinoma Cells* , 2002, The Journal of Biological Chemistry.

[30]  F. Spinella,et al.  Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. , 2001, Cancer research.

[31]  P. Meltzer,et al.  Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. , 2001, Cancer research.

[32]  J. J. van den Oord,et al.  Expression of the endothelin-B receptor in pigment cell lesions of the skin , 2001, Virchows Archiv.

[33]  G. Taraboletti,et al.  Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. , 2000, The American journal of pathology.

[34]  P. Natali,et al.  Role of endothelin-1 in neovascularization of ovarian carcinoma. , 2000, The American journal of pathology.

[35]  J. Morrow,et al.  Regulation of Constitutive Cyclooxygenase-2 Expression in Colon Carcinoma Cells* , 2000, The Journal of Biological Chemistry.

[36]  N. Sampas,et al.  Molecular classification of cutaneous malignant melanoma by gene expression profiling , 2000, Nature.

[37]  D. Elder,et al.  E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. , 2000, The American journal of pathology.

[38]  G. Semenza,et al.  Hypoxia, Clonal Selection, and the Role of HIF-1 in Tumor Progression , 2000, Critical reviews in biochemistry and molecular biology.

[39]  R. DuBois,et al.  The role of cyclooxygenases in inflammation, cancer, and development , 1999, Oncogene.

[40]  P. Patterson,et al.  An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[41]  A. Hartmann,et al.  Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. , 1999, Cancer research.

[42]  M. B. Davis,et al.  Endothelin-1 is a paracrine growth factor that modulates melanogenesis of human melanocytes and participates in their responses to ultraviolet radiation. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[43]  G. Imokawa,et al.  Endothelins secreted from human keratinocytes are intrinsic mitogens for human melanocytes. , 1992, The Journal of biological chemistry.

[44]  J. Morrow,et al.  Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1alpha in non-small cell lung cancer. , 2006, Cancer research.

[45]  R. Lahav.  Endothelin receptor B is required for the expansion of melanocyte precursors and malignant melanoma. , 2005, The International journal of developmental biology.

[46]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[47]  C. Denkert,et al.  Expression of cyclooxygenase 2 in human malignant melanoma. , 2001, Cancer research.

[48]  G. Martin,et al.  Identification of arachidonic acid pathways required for the invasive and metastatic activity of malignant tumor cells. , 1996, Prostaglandins.

[49]  E. Levin.  Mechanisms of disease : endothelins , 1995 .

[50]  D. Morton,et al.  Comparison of histocompatibility antigens on cultured human tumor cells and fibroblasts by quantitative antibody absorption and sensitivity to cell-mediated cytotoxicity. , 1976, Journal of the National Cancer Institute.